HDAC Inhibition in Rheumatoid Arthritis and Juvenile Idiopathic Arthritis

Overview

Journal Mol Med

Publisher Biomed Central

Specialties General Medicine
Molecular Biology

Date 2011 Feb 11

PMID 21308151

Citations 61

Authors

Jelena Vojinovic

Nemanja Damjanov

Affiliations

Soon will be listed here.

Abstract

Rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) are heterogeneous autoimmune diseases characterized by chronic joint inflammation. Methotrexate is used as the gold standard to treat rheumatoid arthritis, yet there are many patients in whom the disease cannot be controlled or who experience unacceptable intolerance. Most of the biologics currently used are effective, but mostly if combined with methotrexate. Long-term possible side effects, such as impaired host defense mechanisms against infection and lymphoma, are distinct disadvantages and a major concern of anticytokine therapies. Parenteral administration is a problem, particularly in children. Thus, there is a need to explore new treatment options. Here we review the properties of histone deacetylase inhibitors (HDACi) as they apply to rheumatoid arthritis by looking at effects on cytokine production, T-cell differentiation and the function of macrophages, dendritic cells, osteoblasts, osteoclasts and synovial fibroblasts. We also review the safety and efficacy of givinostat (ITF 2357) in the treatment of systemic onset juvenile idiopathic arthritis (SOJIA) and its influence on the cytokine networks in SOJIA. Givinostat is an orally active HDACi which was given to children with SOJIA. After 12 wk of treatment, there were significant benefits, particularly in reducing the pain and arthritic component of the disease and decreasing the neutrophilia. CD40L, IL-1α and IFNγ in whole blood lysates decreased at wks 2 and 4 compared with baseline levels. The clinical data are consistent with those from animal models of rheumatoid arthritis and suggest that trials with HDACi are promising as a safe oral alternative to anticytokines and methotrexate.

Citing Articles

Unveiling Novel Drug Targets and Emerging Therapies for Rheumatoid Arthritis: A Comprehensive Review.

Khokhar M, Dey S, Tomo S, Jaremko M, Emwas A, Pandey R ACS Pharmacol Transl Sci. 2024; 7(6):1664-1693.

PMID: 38898941 PMC: 11184612. DOI: 10.1021/acsptsci.4c00067.

Epi-revolution in rheumatology: the potential of histone deacetylase inhibitors for targeted rheumatoid arthritis intervention.

Pai P, Vijeev A, Phadke S, Shetty M, Sundara B Inflammopharmacology. 2024; 32(4):2109-2123.

PMID: 38714604 PMC: 11300544. DOI: 10.1007/s10787-024-01486-z.

ITF2357 regulates NF-κB signaling pathway to protect barrier integrity in retinal pigment epithelial cells.

Lim R, Mahaling B, Tan A, Mehta M, Kaur C, Hunziker W FASEB J. 2024; 38(5):e23512.

PMID: 38430220 PMC: 11019659. DOI: 10.1096/fj.202301592R.

Long non-coding RNA H19 enhances the pro-apoptotic activity of ITF2357 (a histone deacetylase inhibitor) in colorectal cancer cells.

Zichittella C, Loria M, Celesia A, Di Liberto D, Corrado C, Alessandro R Front Pharmacol. 2023; 14:1275833.

PMID: 37841928 PMC: 10572549. DOI: 10.3389/fphar.2023.1275833.

The Role of Selected Epigenetic Pathways in Cardiovascular Diseases as a Potential Therapeutic Target.

Wolowiec A, Wolowiec L, Grzesk G, Jasniak A, Osiak J, Husejko J Int J Mol Sci. 2023; 24(18).

PMID: 37762023 PMC: 10531432. DOI: 10.3390/ijms241813723.

References

Goldbach-Mansky R, Dailey N, Canna S, Gelabert A, Jones J, Rubin B . Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med. 2006; 355(6):581-92. PMC: 4178954. DOI: 10.1056/NEJMoa055137. View

Elaut G, Rogiers V, Vanhaecke T . The pharmaceutical potential of histone deacetylase inhibitors. Curr Pharm Des. 2007; 13(25):2584-620. DOI: 10.2174/138161207781663064. View

Edens R, Dagtas S, Gilbert K . Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: a comparative study. Int Immunopharmacol. 2006; 6(11):1673-81. DOI: 10.1016/j.intimp.2006.07.001. View

Kawabata T, Nishida K, Takasugi K, Ogawa H, Sada K, Kadota Y . Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis. Arthritis Res Ther. 2010; 12(4):R133. PMC: 2945023. DOI: 10.1186/ar3071. View

Manabe H, Nasu Y, Komiyama T, Furumatsu T, Kitamura A, Miyazawa S . Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts. Inflamm Res. 2008; 57(1):4-10. DOI: 10.1007/s00011-007-7036-z. View

Mangge H, Vojinovic J, Schauenstein K . Do chemokines spark autoimmunity in juvenile and adult rheumatic disease?. Immunobiology. 2002; 206(4):459-71. DOI: 10.1078/0171-2985-00194. View

Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S . Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371(9617):998-1006. DOI: 10.1016/S0140-6736(08)60454-7. View

Petty R, Southwood T, Manners P, Baum J, Glass D, Goldenberg J . International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004; 31(2):390-2. View

Ruperto N, Murray K, Gerloni V, Wulffraat N, Knupp Feitosa de Oliveira S, Falcini F . A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004; 50(7):2191-201. DOI: 10.1002/art.20288. View

10.

Schroeder T, Westendorf J . Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res. 2005; 20(12):2254-63. DOI: 10.1359/JBMR.050813. View

11.

Huber L, Stanczyk J, Jungel A, Gay S . Epigenetics in inflammatory rheumatic diseases. Arthritis Rheum. 2007; 56(11):3523-31. DOI: 10.1002/art.22948. View

12.

Perlman H, Bradley K, Liu H, Cole S, Shamiyeh E, Smith R . IL-6 and matrix metalloproteinase-1 are regulated by the cyclin-dependent kinase inhibitor p21 in synovial fibroblasts. J Immunol. 2003; 170(2):838-45. DOI: 10.4049/jimmunol.170.2.838. View

13.

Giannini E, Brewer E, Kuzmina N, Shaikov A, Maximov A, Vorontsov I . Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med. 1992; 326(16):1043-9. DOI: 10.1056/NEJM199204163261602. View

14.

Li X, Yuan F, Lu W, Zhao Y, Li C, Li J . The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis. Biochem Biophys Res Commun. 2010; 397(2):131-5. DOI: 10.1016/j.bbrc.2010.05.111. View

15.

Horiuchi M, Morinobu A, Chin T, Sakai Y, Kurosaka M, Kumagai S . Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J Rheumatol. 2009; 36(8):1580-9. DOI: 10.3899/jrheum.081115. View

16.

Rodrigues H, Jungel A, Gay R, Gay S . Innate immunity, epigenetics and autoimmunity in rheumatoid arthritis. Mol Immunol. 2009; 47(1):12-8. DOI: 10.1016/j.molimm.2009.01.010. View

17.

Halili M, Andrews M, Sweet M, Fairlie D . Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem. 2009; 9(3):309-19. DOI: 10.2174/156802609788085250. View

18.

Young D, Lakey R, Pennington C, Jones D, Kevorkian L, Edwards D . Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res Ther. 2005; 7(3):R503-12. PMC: 1174946. DOI: 10.1186/ar1702. View

19.

Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J . Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005; 201(9):1479-86. PMC: 2213182. DOI: 10.1084/jem.20050473. View

20.

Papagoras C, Voulgari P, Drosos A . Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis. Autoimmun Rev. 2010; 9(8):574-82. DOI: 10.1016/j.autrev.2010.04.002. View